LUCRATIVE FIELD

Eli Lilly to buy gene therapy developer Prevail in deal valued at $1.04 billion

Lilly said it would acquire Prevail for $22.50 per share, which represents a premium of 80% to Monday's closing price. The deal also includes a "contingent value right" worth $4 per share in cash, contingent upon certain milestones being achieved.